CARsgen Therapeutics Holdings (2171.HK) Earnings Analysis
CARsgen Therapeutics Holdings (2171.HK) next reports earnings on 2026-08-25, consensus EPS -0.21938 HKD. Last quarter (2026-03-06) it beat with EPS -0.04452 HKD vs -0.1558 HKD est (+71.4%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -68.80.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 2171.HK next report earnings?
| Next earnings date | 2026-08-25 |
|---|---|
| Consensus EPS estimate | -0.21938 HKD |
| Revenue estimate | 0.11B |
2171.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-06 | -0.04452 HKD | -0.1558 HKD | +71.4% | Beat |
| 2025-08-14 | -0.15341 HKD | -0.43832 HKD | +65% | Beat |
| 2024-12-31 | -0.76785 HKD | n/a | n/a | n/a |
| 2024-08-28 | -0.67689 HKD | -0.27935 HKD | -142.3% | Miss |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
2171.HK valuation and analyst view
| Trailing P/E | -68.80 |
|---|---|
| Trailing EPS | -0.17705 HKD |
| Price / book | 8.76 |
| Dividend yield | 0.00% |
| Market cap | 8.54B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is CARsgen Therapeutics Holdings (2171.HK)'s next earnings date?
CARsgen Therapeutics Holdings is next scheduled to report on 2026-08-25, with a consensus EPS estimate of -0.21938 HKD and revenue estimate of 0.11B.
Did 2171.HK beat earnings last quarter?
In its 2026-03-06 report, 2171.HK posted EPS of -0.04452 HKD versus a -0.1558 HKD estimate — a beat of 71.4%.
What is 2171.HK's earnings track record?
Over the last 3 reported quarters with consensus data, 2171.HK beat estimates 2 times (67%).
What is 2171.HK's current P/E ratio and EPS?
2171.HK trades at a trailing P/E of -68.80 on trailing EPS of -0.17704890739560755 HKD.
What do analysts rate 2171.HK?
2171.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.